Education
About Us
Working with TipRanks
Follow Us
Palvella Therapeutics (PVLA)
NASDAQ:PVLA
PVLA Analyst Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PVLA Stock 12 Month Forecast
Average Price Target
$113.78
▲(50.20% Upside)
| Highest Price Target$200.00 | Average Price Target$113.78 | Lowest Price Target$70.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$95→$190
Buy
150.83%
Upside
Reiterated
11/06/25
Cantor Fitzgerald
$120→$200
Buy
164.03%
Upside
Reiterated
11/06/25
Chardan Capital
$73→$110
Buy
45.21%
Upside
Reiterated
11/06/25
Truist Financial
―
Buy
―
Reiterated
11/06/25
TD Cowen
$65→$97
Buy
28.05%
Upside
Reiterated
11/05/25
LifeSci Capital
$90
Buy
18.81%
Upside
Reiterated
11/05/25
Buy Rating for Palvella Therapeutics: Innovative Approach and Strategic Development in Rare Dermatological TreatmentsThis morning, Palvella (Nasdaq: PVLA) unveiled its first non-rapamycin QTORIN plaorm product, which is QTORIN pitavastan. Pitavastan is an FDA-approved stan (approved for primary hyperlipidemia and mixed dyslipidemia) that acts as an inhibitor of the mevalonate pathway. Palvella will be pursuing the development of QTORIN pitavastan in disseminated superficial acnic porokeratosis (DSAP) to start (with potenal to expand the products reach), which is another rare dermatological disease with no FDA-approved therapies and a sizeable market opportunity with >50k diagnosed U.S. paents, aligning with the Company’s broad pipeline strategy of being first-in- disease and standard-of-care in commercially aracve markets. An FDA meeng is scheduled for H1 2026 to discuss a Phase 2 trial design, with trial iniaon expected in H2 2026 (targeng <2.5 years to Phase 2 proof-of-concept data).
Stifel Nicolaus
$80→$87
Buy
14.85%
Upside
Reiterated
11/05/25
Strategic Expansion of Palvella Therapeutics' QTORIN Platform Targets Unmet Needs in Rare Skin ConditionsWe reiterate our Buy on PVLA, raising TP to $87. PVLA disclosed its newest QTORIN-leveraged program—pitavastatin for disseminated superficial actinic prokeratosis/DSAP, a chronic and debilitating, precancerous rare genetic skin condition with the hallmarks of PVLA’s optimal disease targets. The condition has a clear pathogenesis (mutation in the mevalonate pathway), scientific validation (>20 studies demonstrating direct biological effect), unmet need (no FDA- approved therapies), and a defined population. DSAP is commercially attractive (prevalence 50k patients) and represents the first of several mevalonate-driven conditions that can benefit from this consistent, high-concentration dermal delivery via QTORIN.
Canaccord Genuity
$66→$90
Buy
18.81%
Upside
Reiterated
10/09/25
JonesTrading
$56→$70
Buy
-7.59%
Downside
Reiterated
09/25/25
Oppenheimer
$85→$90
Buy
18.81%
Upside
Reiterated
09/24/25
Raymond James
$54
Buy
-28.71%
Downside
Initiated
08/06/25
Scotiabank
$50
Buy
-33.99%
Downside
Reiterated
07/22/25
Lucid Capital
$49
Buy
-35.31%
Downside
Initiated
03/18/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$95→$190
Buy
150.83%
Upside
Reiterated
11/06/25
Cantor Fitzgerald
$120→$200
Buy
164.03%
Upside
Reiterated
11/06/25
Chardan Capital
$73→$110
Buy
45.21%
Upside
Reiterated
11/06/25
Truist Financial
―
Buy
―
Reiterated
11/06/25
TD Cowen
$65→$97
Buy
28.05%
Upside
Reiterated
11/05/25
LifeSci Capital
$90
Buy
18.81%
Upside
Reiterated
11/05/25
Buy Rating for Palvella Therapeutics: Innovative Approach and Strategic Development in Rare Dermatological TreatmentsThis morning, Palvella (Nasdaq: PVLA) unveiled its first non-rapamycin QTORIN plaorm product, which is QTORIN pitavastan. Pitavastan is an FDA-approved stan (approved for primary hyperlipidemia and mixed dyslipidemia) that acts as an inhibitor of the mevalonate pathway. Palvella will be pursuing the development of QTORIN pitavastan in disseminated superficial acnic porokeratosis (DSAP) to start (with potenal to expand the products reach), which is another rare dermatological disease with no FDA-approved therapies and a sizeable market opportunity with >50k diagnosed U.S. paents, aligning with the Company’s broad pipeline strategy of being first-in- disease and standard-of-care in commercially aracve markets. An FDA meeng is scheduled for H1 2026 to discuss a Phase 2 trial design, with trial iniaon expected in H2 2026 (targeng <2.5 years to Phase 2 proof-of-concept data).
Stifel Nicolaus
$80→$87
Buy
14.85%
Upside
Reiterated
11/05/25
Strategic Expansion of Palvella Therapeutics' QTORIN Platform Targets Unmet Needs in Rare Skin ConditionsWe reiterate our Buy on PVLA, raising TP to $87. PVLA disclosed its newest QTORIN-leveraged program—pitavastatin for disseminated superficial actinic prokeratosis/DSAP, a chronic and debilitating, precancerous rare genetic skin condition with the hallmarks of PVLA’s optimal disease targets. The condition has a clear pathogenesis (mutation in the mevalonate pathway), scientific validation (>20 studies demonstrating direct biological effect), unmet need (no FDA- approved therapies), and a defined population. DSAP is commercially attractive (prevalence 50k patients) and represents the first of several mevalonate-driven conditions that can benefit from this consistent, high-concentration dermal delivery via QTORIN.
Canaccord Genuity
$66→$90
Buy
18.81%
Upside
Reiterated
10/09/25
JonesTrading
$56→$70
Buy
-7.59%
Downside
Reiterated
09/25/25
Oppenheimer
$85→$90
Buy
18.81%
Upside
Reiterated
09/24/25
Raymond James
$54
Buy
-28.71%
Downside
Initiated
08/06/25
Scotiabank
$50
Buy
-33.99%
Downside
Reiterated
07/22/25
Lucid Capital
$49
Buy
-35.31%
Downside
Initiated
03/18/25
Best Analysts Covering Palvella Therapeutics
1 Month
xxx
Success Rate
4/4 ratings generated profit
Average Return
+33.15%
reiterated a xxx
rating yesterday
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +33.15% per trade.
3 Months
xxx
Success Rate
4/4 ratings generated profit
Average Return
+67.70%
reiterated a xxx
rating yesterday
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +67.70% per trade.
1 Year
Success Rate
8/8 ratings generated profit
Average Return
+286.16%
reiterated a buy rating yesterday
Copying Andrew Fein's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +286.16% per trade.
2 Years
xxx
Success Rate
8/8 ratings generated profit
Average Return
+286.16%
reiterated a xxx
rating yesterday
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +286.16% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PVLA Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
10
7
9
9
6
Buy
2
9
17
18
14
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
16
26
27
20
Each month's total comprises the sum of three months' worth of ratings.
PVLA Financial Forecast
PVLA Stock Forecast FAQ
What is PVLA’s average 12-month price target, according to analysts?
Based on analyst ratings, Palvella Therapeutics’s 12-month average price target is 113.78.
What is PVLA’s upside potential, based on the analysts’ average price target?
Palvella Therapeutics has 50.20% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PVLA a Buy, Sell or Hold?
Palvella Therapeutics has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
What is Palvella Therapeutics’s price target?
The average price target for Palvella Therapeutics is 113.78. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $200.00 ,the lowest forecast is $70.00. The average price target represents 50.20% Increase from the current price of $75.75.
The highest analyst price target is $200.00 ,the lowest forecast is $70.00. The average price target represents 50.20% Increase from the current price of $75.75.
What do analysts say about Palvella Therapeutics?
Palvella Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of PVLA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.